Randomized controlled trial comparing impact on platelet reactivity of twice-daily with once-daily aspirin in people with Type 2 diabetes

• Published in: Diabetic medicine Vol. 33; no. 2; pp. 224 - 230
• Main Authors: Bethel, M. A., Harrison, P., Sourij, H., Sun, Y., Tucker, L., Kennedy, I., White, S., Hill, L., Oulhaj, A., Coleman, R. L., Holman, R. R.
• Format: Journal Article
• Language: English
• Published: England Blackwell Publishing Ltd 01.02.2016; Wiley Subscription Services, Inc
• Subjects: Adult; Aspirin - administration & dosage; Aspirin - adverse effects; Aspirin - therapeutic use; Cardiovascular Diseases - complications; Cardiovascular Diseases - epidemiology; Cardiovascular Diseases - prevention & control; Cross-Over Studies; Cyclooxygenase Inhibitors - administration & dosage; Cyclooxygenase Inhibitors - adverse effects; Cyclooxygenase Inhibitors - therapeutic use; Diabetes; Diabetes Mellitus, Type 2 - blood; Diabetes Mellitus, Type 2 - complications; Diabetic Angiopathies - epidemiology; Diabetic Angiopathies - prevention & control; Diabetic Cardiomyopathies - epidemiology; Diabetic Cardiomyopathies - prevention & control; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Drug Resistance; England - epidemiology; Female; Hemorrhage - chemically induced; Hemorrhage - complications; Hemorrhage - epidemiology; Humans; Male; Middle Aged; Platelet Activation - drug effects; Platelet Aggregation Inhibitors - administration & dosage; Platelet Aggregation Inhibitors - adverse effects; Platelet Aggregation Inhibitors - therapeutic use; Risk; Risk Assessment

Aims Reduced aspirin efficacy has been demonstrated in people with Type 2 diabetes. Because increased platelet reactivity and/or turnover are postulated mechanisms, we examined whether higher and/or more frequent aspirin dosing might reduce platelet reactivity more effectively. Methods Participants...